Glaukos Corp

NYSE:GKOSUnited States

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Contact Information

Headquarters

1 GLAUKOS WAYALISO VIEJO, CA, United States 92656

Phone

949-367-9600

Fax

949-367-9984

Executives

Chairman of the Board, Chief Executive Officer

Thomas Burns

President, Chief Operating Officer

Joseph Gilliam

Chief Financial Officer, Senior Vice President

Alex Thurman

Chief Development Officer

Tomas Navratil

Lead Independent Director

Mark Foley